Owkin announced on September 2, 2026 that it has entered a license agreement with Boehringer Ingelheim covering K Pro, Owkin's AI Scientist for biopharma research, together with multimodal patient data aimed at speeding discovery across multiple indications in oncology and immunology. Under the agreement, Owkin will license multimodal oncology data to Boehringer Ingelheim and will generate new multimodal data in immunology, according to the Owkin announcement. Owkin licenses, sources, and…
This article has been indexed from Unite.AI
Read the original article: